CLINICAL_TRIALS ClinicalTrials.gov record update

Randomized Double-Blind Phase 2 Trial of Ibrutinib Versus Standard Treatment for COVID-19 Illness Requiring Hospitalization With Safety Lead-In

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04439006
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:24.047590+00:00
Published At: 2023-12-26T00:00:00+00:00
Record Updated At: 2023-12-26
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Aplastic Anemia", "Hematopoietic and Lymphoid Cell Neoplasm", "Malignant Solid Neoplasm", "Monoclonal B-Cell Lymphocytosis", "Monoclonal Gammopathy of Undetermined Significance", "Myelodysplastic Syndrome", "Symptomatic COVID-19 Infection Laboratory-Confirmed"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2023-12-26"
protocolSection.identificationModule.nctId: "NCT04439006"
protocolSection.identificationModule.officialTitle: "Randomized Double-Blind Phase 2 Trial of Ibrutinib Versus Standard Treatment for COVID-19 Illness Requiring Hospitalization With Safety Lead-In"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.